Professional
Added to YB: 2024-02-26
Pitch date: 2024-01-15
NVO [bullish]
Novo Nordisk A/S
-58.08%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 677.85
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
growth
Polen Global Growth Added to Existing Position - Novo Nordisk
Novo Nordisk, new strategy addition, saw Q4 position building to avg weight. Danish pharma pioneer in insulin for diabetes, now focusing on GLP-1 drugs effective for blood sugar control & significant weight loss. With obesity a global epidemic causing adverse health outcomes, payors seen increasingly recognizing value of obesity treatments for patients & healthcare system over time.
Read full article (1 min)